Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.57 |
| ▸ | CA1 | P00915 | 5/20 | 0.57 |
| ▸ | CA2 | P00918 | 5/20 | 0.57 |
| ▸ | CA7 | P43166 | 5/20 | 0.57 |
| ▸ | CA9 | Q16790 | 5/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.57 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1175094 | 0.90 | HRH3 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8023880 | 0.90 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7592360 | 0.87 | ESR1 (0.60) | ESR1TSHRLMNACYP1A2CYP3A4 | |
| SCHEMBL277473 | 0.86 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22468902 | 0.86 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30294421 | 0.84 | TSHR (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22852761 | 0.84 | TSHR (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5273471 | 0.84 | ALDH1A1 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL670944 | 0.84 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30349688 | 0.84 | CA12 (0.59) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407770-B2 | Amphiphobic porous materials | UNIVERSITY OF SOUTH FLORIDA (US) | 2022-08-09 | — | — | US | disclosed |
| US-20190345171-A1 | AMPHIPHOBIC POROUS MATERIALS | NATIONAL SCIENCE FOUNDATION | 2019-11-14 | — | — | US | disclosed |
| EP-3565803-A1 | AMPHIPHOBIC POROUS MATERIALS | University of South Florida (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018129406-A1 | AMPHIPHOBIC POROUS MATERIALS | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-07-12 | — | — | WO | disclosed |
| CN-104245786-A | Conjugated polymers | MERCK PATENT GMBH | 2014-12-24 | — | — | CN | disclosed |
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100317854-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7781470-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-24 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-6323373-B1 | USED TO OBTAIN POLYMERS WHICH ARE USED AS ELECTROLUMINESCENCE MATERIALS | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 2001-11-27 | — | — | US | disclosed |
| WO-2001019780-A2 | NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| CN-1244855-A | Polymerizable biaryls, method for the production and use thereof | HOECHST RES & TECH GMBH & CO (DE) | 2000-02-16 | — | — | CN | disclosed |
| CN-1244206-A | Aryl-substituted poly (p-arylene-vinylenes), method for the production thereof and use thereof in electroluminescent elements | AWENTIS RESEARCH AND TECHNOLOG (DE) | 2000-02-09 | — | — | CN | disclosed |
| EP-0944663-A1 | ARYL-SUBSTITUTED POLY(p-ARYLENE VINYLENES), METHOD FOR THE PRODUCTION AND USE THEREOF IN ELECTROLUMINESCENT COMPONENTS | Celanese Ventures GmbH (DE) | 1999-09-29 | — | — | EP | disclosed |
| EP-0944569-A1 | POLYMERIZABLE BIARYLS, METHOD FOR THE PRODUCTION AND USE THEREOF | Aventis Research & Technologies GmbH & Co. KG (DE) | 1999-09-29 | — | — | EP | disclosed |
| US-5880309-A | DIALKYL DIALKOXYCARBONYLPHENYL PHOSPHONATES USEFUL AS RESIN MODIFIERS PRODUCED AT HIGH YIELD AND LOW COST BY HEATING A TRIALKYL PHOSPHITE AND A DIALKOXYCARBONYLPHENYL HALIDE IN THE PRESENCE OF A PALLADIUM OR NICKEL CATALYST AND HYDROLYZING | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-09 | — | — | US | disclosed |
| EP-0855400-A1 | Phenylphosphonic acid derivative and production process therefor | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| WO-1998027136-A1 | ARYL-SUBSTITUTED POLY(p-ARYLENE VINYLENES), METHOD FOR THE PRODUCTION AND USE THEREOF IN ELECTROLUMINESCENT COMPONENTS | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998025874-A1 | POLYMERIZABLE BIARYLS, METHOD FOR THE PRODUCTION AND USE THEREOF | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | CA12 4274/4885CA1 4797/4885CA2 4212/4885 |
| US-20100317854-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | DDC, AADAT, PTGIS | CA12 1661/4885CA1 3885/4885CA2 807/4885 |
| US-11407770-B2 | Amphiphobic porous materials | FABP4, ABHD16A, AQP4 | CA12 1262/4885CA1 791/4885CA2 2274/4885 |
| US-20190345171-A1 | AMPHIPHOBIC POROUS MATERIALS | FABP4, ABHD16A, AQP4 | CA12 1262/4885CA1 791/4885CA2 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.